Duquesne Family Office’s Caribou Biosciences CRBU Stock Holding History

Duquesne Family Office’s Portfolio CRBU Stock Details CRBU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-271,430	Closed	-$2.86M	–	64
2022 Q3	$2.86M	Hold	271,430	–	–	0.16%	55
2022 Q2	$1.47M	Hold	271,430	–	–	0.11%	36
2022 Q1	$2.49M	Hold	271,430	–	–	0.11%	45
2021 Q4	$4.1M	Hold	271,430	–	–	0.15%	42
2021 Q3	$6.48M	Buy	+271,430	New	+$6.64M	0.21%	39

Other funds holding CRBU

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

RCMU

Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

EWM

Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Duquesne Family Office's CRBU Position: Q4 2022 in Review

Duquesne Family Office sold out of Caribou Biosciences (CRBU) in Q4 2022, closing a stake of 271,430 shares — an estimated $2.86M sold.

Duquesne Family Office first reported a position in CRBU in Q3 2021 and held it in 5 quarters. The position peaked at $6.48M in Q3 2021. 133 funds tracked by Wall St. Rank hold CRBU as of Q4 2022.

Duquesne Family Office reported no remaining Caribou Biosciences position as of Q4 2022 after selling out during the quarter.
Duquesne Family Office sold 271,430 Caribou Biosciences shares in Q4 2022, an estimated $2.86M.
Duquesne Family Office first reported a position in Caribou Biosciences in Q3 2021 and held it in 5 quarters.
Duquesne Family Office's Caribou Biosciences position peaked at $6.48M in Q3 2021.
133 funds tracked by Wall St. Rank held Caribou Biosciences as of Q4 2022.

Based on Duquesne Family Office's 13F filing for Q4 2022, filed 14 Feb 2023.